Cancer Immunology Immunotherapy Journal Citation Rate 2026

ISSN 0340-7004 eISSN 1432-0851 Springer Science+Business Media DE

Q1 Quartile Open Access Established Impact

About Cancer Immunology Immunotherapy
{# Self-contained "answer block": one dense, LLM-quotable paragraph stating every core fact with an explicit as-of year, server-rendered and unique per journal. This is the canonical fact statement — other sections add narrative, they do not restate these numbers. #}

Cancer Immunology Immunotherapy (CII) is a peer-reviewed academic journal covering CAR-T cell therapy research and Cancer Immunotherapy and Biomarkers, published by Springer Science+Business Media in DE, catalogued under ISSN 0340-7004 (e-ISSN 1432-0851). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 4.62 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It is fully open access, with an Article Processing Charge (APC) of approximately $4390 USD.

Cancer Immunology Immunotherapy Citation Rate 2026 — In Context

Cancer Immunology Immunotherapy has a 2025 2-Year Citation Rate (OpenAlex) of 4.62, placing it in the Q1 quartile within the CAR-T cell therapy research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.

As a fully open-access publication, Cancer Immunology Immunotherapy makes all articles freely available to readers for an Article Processing Charge of approximately $4390 USD.

Researchers looking to publish in Cancer Immunology Immunotherapy should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Cancer Immunology Immunotherapy against similar journals in the field, use our journal comparison tool.

Submission Tips for Cancer Immunology Immunotherapy
  • Budget $4390 for the Article Processing Charge. Check if your institution or funder covers OA fees.
  • This journal covers CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Cancer Immunology Immunotherapy Compares
Citation Rate vs Field Avg
+37%
Field avg: 3.38
APC vs Field Avg
+15%
Field avg: $3834

Compared against 31 journals in the same research areas.

ISSN (Print) 0340-7004
ISSN (Online) 1432-0851
Publisher Springer Science+Business Media
Country Germany
APC / Cost $4390 USD
In-depth profile & metrics

Cancer Immunology Immunotherapy is published by Springer Science+Business Media and based in Germany. It publishes open access with an article-processing charge of USD 4390.

In our subject taxonomy, Cancer Immunology Immunotherapy is classified under CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction and Immunotherapy and Immune Responses.

Cancer Immunology Immunotherapy is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.

Its most recent citation rate stands at 4.624.

Research Areas
Links
Frequently Asked Questions about Cancer Immunology Immunotherapy

Cancer Immunology Immunotherapy does not hold a Clarivate (JCR) Impact Factor on JournalsHub. Its 2-year citation rate, computed from OpenAlex open citation data, is 4.624 — an open proxy for citation impact, not the licensed JCR Impact Factor.

Yes, Cancer Immunology Immunotherapy is an open access journal.

The Article Processing Charge (APC) for Cancer Immunology Immunotherapy is $4390 USD.

Cancer Immunology Immunotherapy is published by Springer Science+Business Media.

Cancer Immunology Immunotherapy shows strong legitimacy signals: it is indexed in DOAJ, OpenAlex. Indexing in recognised databases such as Scopus and DOAJ is a reliable indicator of a peer-reviewed, non-predatory journal, because predatory titles are typically excluded from them. Always confirm the journal's scope and editorial board fit your work before submitting.

The ISSN of Cancer Immunology Immunotherapy is 0340-7004. Its electronic ISSN (eISSN) is 1432-0851.

Cancer Immunology Immunotherapy sits in the Q1 quartile based on its latest impact factor of 4.62, ranked across all journals in our database.
Live Indexing Status
Updated April 2026

Track real-time indexing metrics to ensure this journal meets your academic requirements.

OpenAlex
Verified
DOAJ
Indexed OA
Predatory Check
Clean
Citation Rate
4.624
2-Year Citation Rate (OpenAlex) · 2025
Historical Trend
Initial data points only
Citation Rate by Year
Year Value Source
2025 4.624 2-Year Mean Citedness (OpenAlex)

Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.

Compare Journals

Compare Cancer Immunology Immunothera… against similar publications in its field:

Related Journals in Your Field

Metadata

Last updated: Apr 24, 2026

Updated by: openalex_bulk

OpenAlex ID: S203303425

Get weekly updates for CAR-T cell therapy research journals

Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now
Compare 0 Open → Clear
Save your viewing history
You've browsed several journals this session. Sign in to track them in one place and get weekly impact-factor updates.
Save with Google